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Abstract
Our aim was to systematically evaluate the benefits of degarelix as antagonist versus agonists of gonadotropin-releasing hormones
(GnRH) for the treatment of advanced prostate cancer (PC). This comparison was performed either in terms of biochemical or
oncological or safety profiles. To this end we, carried out a systematic review and meta-analysis of the literature.
We selected only studies directly and prospectively analyzing the two treatments in the same population (randomized phase III
studies). We followed the Preferred Reporting Items for Systematic Reviews and meta-analyses process for reporting studies.
After we eliminated studies according to the exclusion criteria, 9 publications were considered relevant to this review. These articles
described 5 clinical trials that were eligible for inclusion. The follow-up duration in all trials did not exceed 364 days. This meta-analysis and
review comprised a total of 1719men, 1061 randomized to degarelix versus 658 toGnRH agonists treatment for advanced PC.Oncological
results were evaluated only in 1 trial (CS21:408 cases) and they were not the primary endpoints of the study. Treatment emerging adverse
events were reported in 61.4% and 58.8% of patients in the degarelix and GnRH agonists group, respectively (odds ratio, OR=1.17; 95%
confidence interval, 95% CI: 0.78–1.77, P>0.1). Treatment related severe cardiovascular side effects were reported (trial CS21-30-35) in
1.6% and 3.6% of patients in the degarelix and GnRH agonists group, respectively (OR=0.55, 95% CI: 0.26–1.14, P>0.1).
Our analysis evidences relevant limitations in particular for the comparative evaluation of the efficacy and the oncological results
related to degarelix.
Abbreviations: ADT = Androgen deprivation therapy; CAB = Complete androgen blockade; CRPC = castrate resistant PC;
GnRH= gonadotropin- releasing hormones; PC= prostate cancer; QUADAS=Quality Assessment of Diagnostic Accuracy Studies.
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11. Introduction
Androgen deprivation therapy (ADT) is the basis of the
medical treatment for advanced prostate cancer (PC) and is
increasingly used in combination with radiotherapy in patients
with earlier stages of disease.[1] For several years gonadotro-
pin-releasing hormones (GnRHs) agonists have been the
standard of care for ADT. More recently GnRH antagonists
represent an alternative form of ADT and degarelix is the main
compound used and analyzed in clinical trials. GnRH
antagonists demonstrated a direct and immediate action that
allows castration without an initial testosterone surge or
subsequent microsurges as reported with agonists.[2] A
comparative analysis on GnRH antagonists versus agonists
on PC cases has been produced in some prospective and
randomized clinical trials with more data on biochemical
modifications than on oncologic results.[3]
Despite the relevant role of ADT in PC, most patients showing
an initial response will experience progression to a castrate
resistant PC (CRPC). A better choice of the compound to be used
for castration and a better pharmacological sequentiality in the
hormone-sensitive phase of the disease may help to delay the
development of CRPC. International guidelines[1,4] recommend
the use of both GnRH agonists and antagonists as possible
alternatives for ADT in PC. The present meta-analysis and review
evaluates the comparative efficacy and safety of degarelix as
specific antagonist and GnRH agonists for PC.
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Figure 1. flow-chart showing the numbers of papers identified and included or excluded at each stage of our analysis.
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2.1. Objective
Our aim was to systematically evaluate the benefits of degarelix
as antagonist versus agonists of GnRH for the treatment of
advanced PC. This comparison was performed either in terms of
biochemical or oncological or safety profiles. To this end, we
carried out a systematic review and meta-analysis of the
literature.2.2. Search strategy
For each database examined, the search terms used were
(“prostate neoplasm”) AND (“degarelix” OR “gonadotropin-
releasing hormone antagonist”) AND (“gonadotropin-releasing
hormone agonist” OR “luteinizing-releasing hormone agonist”
OR “luteinizing-releasing hormone analogue”). A critical review
of Embase, Medline (OvidSP), Web of Science, Scopus, PubMed,
Cinahl, clinicaltrial.gov, and the Cochrane library was per-
formed. The search was updated to July 30, 2015.2.3. Inclusion and exclusion criteria
Inclusion criteria focused on men of all age groups with
histologically proved PC treated with degarelix (as GNRH
antagonist) versus GnRH agonists inside clinical trials. We
selected only studies directly and prospectively analyzing the two
treatments in the same population (only randomized phase III
studies) to compare them in the most objective manner. We
included and reviewed original articles, clinical trials, and
reviews. In addition abstracts from trials were used only to
update current information on trials already and entirely
presented. There were no restrictions on the basis of years and2language, but we included only trials conducted in humans. We
excluded unpublished data or published only as abstracts because
the information that is needed to correctly assess the study quality
and results was not completely available. We also excluded
reports with GnRH antagonists other than degarelix.
2.4. Data collection and data extraction
We followed the Preferred REPORTING Items for Systematic
Reviews and meta-analyses (PRISMA) process[5,6] for reporting
studies, with the recommended flow-chart showing the numbers
of papers identified and included or excluded at each stage
(Fig. 1). The entire publications were reviewed for relevance to
the defined review question. The references cited in all full-text
articles were also assessed for additional relevant articles.[6] The
search was carried out by two reviewers (AS and SS)
independently. From each study, data regarding methodology,
patient population, trials design, treatments, baseline parameters,
biochemical assessments, oncologic efficacy assessments, safety,
and quality of life analysis were extracted. We considered three
populations: general population considered in the study, only
nonmetastatic and only metastatic cases (when possible in the
study). Data were extracted in 2X2 contingency tables.
2.5. Assessment of publication bias and study quality
To analyze the presence of publication bias, log-transformed
values of the relative sensitivity were plotted against the
associated standard errors for graphical inspection (funnel plot).
In addition, asymmetry of the funnel plot was tested using the
Egger regression test. Identified reports were reviewed according
either to the Quality Assessment of Diagnostic Accuracy Studies
(QUADAS) criteria[6,7] or the Cochrane collaboration’s tool.
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In each study, we compared degarelix versus GnRH agonist’s
outcomes either in the whole population considered or only in
metastatic or nonmetastatic cases (when possible). The compari-
son was conducted on different profiles: biochemical (outcomes
on PSA, testosterone, and gonadotropins), oncological (overall
survival, PC specific survival, clinical progression frees survival,
and biochemical progression-free survival), safety profile, quality
of life (symptoms and quality of life questionnaires).
To synthesize the results, we performed both Fixed-Effects and
Random-Effects meta-analysis comparing the two treatment
regimens. A fixed-effect analysis provided a results that may be
viewed as a “typical intervention effect” from the studies
included. In order to calculate a confidence interval for a fixed-
effect analysis the assumption is made that the true effect of
intervention is the same value in each study. This assumption
implies that there is no statistical heterogeneity. In case of
heterogeneity a random-effect model is incorporate and it
involves the assumption that the effects being estimated in the
different studies are not identical. In case for all studies included
also standard deviations are always available, the standardized
mean difference method is used.
Survival rate was used as a binary variable in all the included
studies. Therefore, the log of the odds ratio (OR) and the 95%
confidence interval (CI) were reckoned as the effect size for each
considered endpoint. The OR and 95% CI results could be
divided into the following: (i) OR >1 and 95% noncontaining 1,
rate was significantly higher in the degarelix group; (ii) OR <1
and 95% CI not containing 1, rate was significantly higher in the
GnRH agonist group; (iii) OR=1, no difference in the rates of the
two groups; and (iv) 95% CI containing 1, statistically
insignificant difference in the rates of the two groups. All
statistical analysis were performed using R 3.2.0.2.7. Heterogeneity
Heterogeneitywas assessed using anX2 statistic and the I2 statistic.
A continuity correction was applied where necessary. If heteroge-
neity was not present (P>0.10 and I2<50%), the fixed-effects
model would be selected for further analysis. We performed
subanalysis for two defined subgroup categories: clinically defined
metastatic PC and clinically defined nonmetastatic PC.
From the studies, different GnRH agonists were used;
however, we considered these treatments as a homogeneous
group to be compared with degarelix treatment. We analyzed as
different groups cases treated with antiandrogen only for the
flare-up period or in association with GnRH agonists for all the
period [complete androgen blockade (CAB)].
3. Results
After we eliminated studies according to the exclusion criteria, 9
publications were considered relevant to this review.[8–16] These
articles described five clinical trials that were eligible for inclusion
in this review and meta-analysis. Data from trial CS35 were
obtained only from clinicaltrial.gov[17] and no extensive
publications are available. All trials were prospective and
randomized and the sample size ranged from 40 to 848 PC
cases. Table 1 shows individual data on the methodology, patient
population, treatments, baseline parameters, biochemical assess-
ments, oncologic efficacy assessments, safety, and quality of life
analysis. The follow-up duration was not the same in the included
studies, but in all trials it did not exceed 364 days.3Data from an extension of trial CS21 (CS21A)[18,19] and trial
CS35 (CS35A)[20] have not been included in our analysis because
they represent a crossover or an open label extension of the main
trial and no new randomized comparative data are available.
This meta-analysis and review comprised a total of 1719 men,
1061 randomized to degarelix versus 658 to GnRH agonists
treatment for advanced PC. A stratification of cases in metastatic
and nonmetastatic PC was possible in four trials (151 metastatic
and 720 non metastatic cases). All cases treated with GnRH
agonists received antiandrogens only for the flare suppression
and no cases were treated with CAB.
As GnRH agonist in 1 trials (CS21: 201 cases) was
administered leuprolide 7.5mg/month whereas in 3 trials
(CS28-30-31: 174 cases) goserelin 3.6mg/month and in 1 trial
(CS35: 283 cases) goserelin 10.8mg/3 months depot.
As GnRH antagonists, degarelix was administered in 4 trials
(496 cases) with a starting dose of 240mg for 1 month and
thereafter monthly doses of 80mg and in 1 trial (CS35: 565 cases)
with 480mg/3 months depot doses. In 1 trial (CS21:202 cases),
there was also a third group of comparison in which degarelix was
administeredafter the startingdosewith amonthly dose of160mg.
3.1. Biochemical profile
The biochemical profile was evaluated in all trials (1719 cases)
and in 2 trials (CS21-35), it was the primary endpoint. In
particular data were evaluated regarding serum PSA, testoster-
one, and gonadotropin levels variation during treatments.
The follow-up duration was not the same in the included
studies, but in all trials, it did not exceed 364 days.
Both treatments (GnRH agonists and degarelix) were able to
maintain testosterone suppression to castration levels 0.5ng/mL
or less from day 28 to day 364. Castration testosterone levels
were obtained and maintained for all the follow-up in 98% and
96% of cases treated with degarelix and GnRH agonists,
respectively (P=0.64).
From day 0 to day 28, treatment with degarelix produced
castration testosterone levels in a higher percentage (97%) of
cases when compared to GnRH agonists (45%; P=0.02).
Ameta-analysis on testosteronedata is not possiblebecause trials
considered testosterone heterogeneously and not comparably.
The analysis of PSA variation was possible in 4 out of the 5 trials
(CS31-30-21-35). From day 0 to day 28, PSA levels declined by 78%
and71% in the degarelix andGnRHagonist group, respectively (P=
0.59). The differences in PSA reduction from baseline at day 28
between degarelix and GnRH agonists were not statistically
significant (OR=1.48, 95% CI: 0.78–2.81, P>0.1, Fig. 2).
Only the CS 21 trial measured the differences in the reduction
in FSH from baseline to the last follow-up (364 days) which were
significantly higher in the degarelix (88.5% reduction) than in the
GnRH agonist (54.8% reduction) group (P values are not
reported).
3.1.1. Summary of findings. Both treatments were able to
maintain testosterone to castration levels to day 364. In the first
28 days, degarelix produced castration levels in a higher
percentage of cases. No significant differences were found
regarding PSA level variation.
3.2. Oncological results
Oncological results were evaluated only in 1 trial (CS21:408
cases) and they were not the primary endpoints of the study. Since
just 1 trial collected oncological data, it was not possible to
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Table 1
Characteristics and Populations of RCT Phase III Included in the Analysis.
Identifier Population Follow-up End points
Reference Year Study arms Number of cases
Age (mean±SD or
median; range; years)
Clinical stage;
Metastatic (number
cases); Nonmetastatic
(number of cases)
PSA at baseline
(mean±SD and/or
median; range; ng/mL) (months) Primary Secondary
CS31 Axcrona[8] 2012 Degarelix 240/80mg; vs.
Goserelin 3.6mg
Degarelix 82;
Goserelin 97
Degarelix 71.9±7.71;
Goserelin 73±7.1
Metastatic 53;
Nonmetastatic 126
Degarelix 277±937; 27.8
(1.9–6206); Goserelin 148±
438; 15.6 (3–2829)
3 TVP reduction LUTS relief, changes of
quality of life (QoL) related
to urinary symptoms
CS28 Anderson[9] 2013 Degarelix 240/80mg; vs.
Goserelin 3.6mg
Degarelix 27;
Goserelin 13
Degarelix 68 (53–87);
Goserelin 72 (57–85)
Metastatic 14;
Nonmetastatic 26
Degarelix 54.5 (8–1914);
Goserelin 41.1 (14.6–348)
3 Change in IPSS Change in Qmax, prostate
size, serum T
concentration, PSA levels,
and changes of Qol
CS30 Mason[10] 2013 Degarelix 240/80mg; vs.
Goserelin 3.6mg
Degarelix 180;
Goserelin 64
Degarelix 70.6±6.37;
Goserelin 70.8±5.96
Metastatic 0;
Nonmetastatic 244
Degarelix 17.4±30.1; 10
(2.5–339); Goserelin 13.4±
12.9; 9.75 (2.9–80)
3 TVP reduction LUTS relief, changes of Qol
related to urinary
symptoms
CS21 Klotz–Tombal–
Lee–Smith[11–14]
2008 Degarelix 240/80mg; vs.
Degarelix 240/160mg; vs.
Leuprolide 7.5mg
Degarelix (240/80
mg) 207;
Leuprolide 201
Degarelix 72 (51–89);
Leuprolide 74 (52–98)
Metastatic 84;
Nonmetastatic 324
Degarelix 19.8 (9.4–46);
Leuprolide 17.4 (8.4–56)
12 Testosterone
analysis
PSA changes, QoL, safety,
PSA recurrence, overall
survival
CS35 Shore[17] 2014 Degarelix 240/480mg; vs.
Goserelin acetate 10.8 mg
Degarelix 565;
Goserelin 283
Degarelix 71.9±8.3;
Goserelin 71.1±7.9
Not defined Degarelix 19.0 (0.26–8762);
Goserelin 19.1 (0.01–12961)
12 Testosterone
analysis
PSA changes, change
in Qol, IPSS
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Figure 2. Meta-analysis of PSA variation comparing degarelix versus GnRH agonist therapy groups.
Sciarra et al. Medicine (2016) Vol:No www.medicine.comperform meta-analysis. Oncological results are summarized in
Table 2.
In particular, data were evaluated regarding overall survival
and PSA progression free survival. On the contrary, the trial
(CS21) did not analyze data regarding PC specific survival and
clinical progression free survival. The follow-up duration was
364 days.
Regarding overall survival, the outcomes ofCS21 trial suggested
that at 364 days, it was significantly (P=0.05; log-rank)) higher in
patients receiving degarelix (97.4%; 95% CI: 93.8–98.9)
compared to GnRH agonists (95.1%; 95% CI: 90.7–97.4). The
study shows that the overall causes of deaths occurred more
frequently in patients receiving GnRH agonists (9 cases=4%)
compared to degarelix (5 cases=2%). However at a limited
follow-up of 364days, the numbers of events (all causes deaths and
PC related deaths) were very low in both groups and this aspect
strongly reduces the significance of overall survival evaluation.
PSA progression-free survival was analyzed in a follow-up of
12 months. The outcomes from CS21 trial suggested that PSA
progression occurred more frequently in cases receiving GnRH
agonist (12.9%) compared to degarelix (7.7%). The probability
of arriving at the final follow-up (12 months) without PSA
progression was higher in patients receiving degarelix (91.1%;
95%CI 85.9–94.5) compared to GnRH agonist (85.9%; 95%CI:
93.8–98.9; P=0.05; log-rank). Adjusting for baseline disease
stage and PSA, this data resulted in HR of 0.664 (95% CI:
0.385–1.146).
PSA progression occurred more frequently in patients with
metastatic disease in both treatment groups (21.6% with
degarelix and 36.2% with leuprolide: P=0.156). Moreover,
PSA progression occurred more frequently in patients with
baseline PSA more than 20ng/mL in both treatment groups
(7.7% with degarelix and 12.9% with leuprolide: P=0.04).
The proportion of patients achieving a PSA suppression less
than 4ng/mL at day 28 was 59% versus 34% in the degarelix andTable 2
Oncological Results from Trial CS21.
Oncological Results at 365 Days F.U. Degarelix
Overall survival 97.4% (CI: 93.8–
PSA progression 7.7%
Probability of survival free of PSA progression 91.1% (CI: 85.9–
PSA progression-free survival in metastatic cases 21.6%
PSA progression-free survival in cases with PSA>20ng/mL 92.3%
5leuprolide groups, respectively (P<0.0001). At day 364, corre-
sponding proportionswere 83%and78% (P=0.339).Overall the
proportion of patients achieving PSA less than 4ng/mL over time
was similar in both treatment groups, although achievement of
PSA less than 4ng/mL was faster with degarelix. For patients with
metastatic disease, a higher proportion of those receiving degarelix
achieved PSA less than 4ng/mL over the duration of the study
(percentages are not specified in the CS21 trial).
3.2.1. Summary of findings. Results were mainly presented in
terms of PSA progression, with a significantly higher PSA
progression free survival in the degarelix group compared to
GnRH agonist. PSA progression occurred more frequently in
metastatic and PSAmore than 20ng/mL cases in both treatments.3.3. Safety profile
Safety profile was evaluated in all 5 Trials (1719 cases), but in no
trial, it was the primary endpoint. The follow-up duration was
not the same in the included studies, but in all trials, it did not
exceed 364 days. Treatment emerging adverse events were
reported in 61.4% and 58.8% of patients in the degarelix and
GnRH agonists group, respectively (OR=1.17, 95% CI:
0.78–1.77, P>0.1, Fig. 3).
Most reported adverse events were mild tomoderate (serious in
3% and 3.5% of cases treated with degarelix and GnRH
agonists, respectively).
Drop-out from the study due to adverse events were low in
both groups (5.5% with degarelix and 4.4% with GnRH
agonists; OR=1.29, 95% CI: 0.81–2.07, P>0.1, Fig. 4).
Differences in the incidence of each of the most common
treatment-related adverse events are reported in Fig. 5. The most
frequently reported adverse event was flushing (29% with
degarelix and 27% with GnRH agonists; OR=1.06, 95% CI:
0.84–1.33, P>0.1 Fig. 6).Leuprolide P Value
98.9) 95.1% (CI: 90.7–97.4) 0.05
12.9% (not determined)
94.5) 85.9% (CI: 93.8–98.9) 0.02 HR: 0.664; CI: 0.385–1.146
36.2% 0.156
87.1% 0.04
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Figure 4. Meta-analysis of dropout from the study due to adverse events comparing degarelix versus GnRH agonists therapy groups.
Figure 3. Meta-analysis of emerging adverse events comparing degarelix versus GnRH agonist therapy groups.
Sciarra et al. Medicine (2016) Vol:No MedicineFigure 5. differences in the incidence of the most common treatment related adverse events.
Figure 6. Meta-analysis of adverse event flushing comparing degarelix versus GnRH agonist therapy groups.
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Figure 7. Meta-analysis of injection-site reaction adverse event comparing degarelix versus GnRH agonist therapy groups.
Sciarra et al. Medicine (2016) Vol:No www.medicine.comDegarelix was associated to a higher rate (49%) of injection-
site reactions than GnRH agonists (0.6%; OR=10.62, 95% CI:
2.94–38.31, P<0.0001, Fig. 7).
Treatment-related severe cardiovascular side effects (QT
interval increase, angina pectoris, atrial fibrillation, cardiac
failure, and myocardial ischemia) were reported (trial CS21-30-
35) in 1.6% and 3.6% of patients in the degarelix and GnRH
agonists group, respectively (OR=0.55, 95%CI: 0.26–1.14, P>
0.1, Fig. 8).
3.3.1. Summary of findings. In both groups, adverse events
were mild or moderate and dropout rate was comparable and
low. The main side effect related to degarelix was site injection
reactions. Severe cardiovascular side effects were lower, but not
significantly, in the degarelix group.Figure 8. Meta-analysis of severe cardiovascular side effect c
Figure 9. Meta-analysis of LUTS variation comparing
73.4. Symptoms and quality of life analysis
Symptoms and quality of life were analyzed in 4 trials (CS28-30-
31-35: 1311 cases) and in 3 trials (CS28-30-31), they were the
primary endpoints. In all trials the IPSS questionnaire was used;
in one trial (CS35) also the BPH Impact Index and the SF-12 /SF-
36 were reported.
The follow-up duration was not the same in the included
studies, but in all trials it did not exceed 364 days.
Lower urinary tract symptoms (LUTS) estimated by the IPSS
questionnaire, showed a higher decrease in the degarelix (5%)
than in the GnRH agonists (3%) group during the follow-up
(MD=2.03, 95% CI: 3.43 to 0.64, P<0.01, Fig. 9).
The reduction of prostate volume after 90 days (last follow-up
in which it was analyzed) was similar in the degarelix (38%) andomparing degarelix versus GnRH agonist therapy groups.
degarelix versus GnRH agonist therapy groups.
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Figure 10. Meta-analysis of prostate volume reduction comparing degarelix
versus GnRH agonist therapy groups.
Sciarra et al. Medicine (2016) Vol:No Medicinein the GnRH agonist (34%) group (MD=3.79, 95% CI: 4.84
to 12.41, P=0.38, Fig. 10).
Improvement in quality of life was differently expressed in the
4 trials and a meta-analysis of data is not possible. However all
studies reported a significantly (P<0.05) higher improvement in
the degarelix group versus the agonist group.
3.4.1. Summary of findings. LUTS showed a significantly
higher reduction in the degarelix group whereas prostate volume
reduction was similar compared to GnRH agonist.
4. Discussion
For many years GnRH agonists have been the ADT standard of
care. There are, however, different drawbacks related to the
mechanism of action: in particular the initial testosterone surge
delays the development of castration levels. Such as for GnRH
agonists, several GnRH antagonists have been synthesized and
analyzed. However, most of clinical trials and international
guidelines recommendations are referred to degarelix.[1–4] For
this reason, we limited our meta-analysis to randomized clinical
trials comparing degarelix to GnRH agonists.
Our aimwas to systematically evaluate the benefits of degarelix
for the treatment of advanced PC. This comparison was
performed either in terms of biochemical or oncological or
safety profiles. To this end we carried-out a systematic review and
meta-analysis of the literature. We only selected studies directly
and prospectively analyzing the two treatments in the same
population (randomized phase III studies), to compare them in
the most objective manner. However the source of the
heterogeneity observed in our meta-analysis is related to different
characteristics of trials: population, follow-up, and different
choice of GnRH agonist.
Our review identified several articles on this topic; 9 papers were
considered relevant to this review and these describe only 5 clinical
phase III trials that were eligible for inclusion in our meta-
analysis.[8–17] On the basis of the limited number of trials and the
limited population included in some of these (ranged from 40 and
848 cases), we decided to do not stratify results on the basis of the
type of the agonist used (leuprorelin andgoserelin).Moreover, only
a comparison between degarelix and GnRH agonist associated to
antiandrogen for theflare up suppressionwas possible.Wehave no
randomized data comparing degarelix with a CAB.8Our analysis confirms that most of significant information
from the randomized clinical trials is referred to the biochemical
profile of the two treatments and this was the primary end point
in 2 trials. All trials showed that both treatments (GnRH agonists
and degarelix) were able to maintain testosterone suppression to
castration levels to day 364. Unfortunately, the long-term
maintenance of testosterone castration was randomly analyzed
only for the first 12 months of treatment. From day 0 to day 28,
using degarelix, castration testosterone levels are reached rapidly
with no surge. Improved short-term testosterone control with
degarelix can have immediate implications, in particular in terms
of symptoms. Symptoms are another well-studied parameter with
data from 4 trials (1311 cases) and in 3 trials they were the
primary endpoints. The comparative analysis of symptoms is
mainly based on the IPSS questionnaire and our meta-analysis
showed a significantly higher decrease in LUTS in the degarelix
than in the GnRH agonists group during the follow-up (MD=
2.03, 95% CI: 3.43 to 0.64, P<0.01).
It should be relevant to have more randomized data on other
categories of symptoms (related to the oncological progression),
such as more structured data on the quality of life profile. Lee
et al.[13] analyzed quality of life improvement from trial CS21.
Using the SF-12 questionnaire authors suggested that degarelix,
slowing PSA progression may improve patient health related
quality of life. However, when controlling for utility estimates
and factors expected to be influenced by treatment (adverse
events and PSA progression), there was no significant effect of
treatment (degarelix versus leuprolide) on quality of life.
Some studies[10] suggested a possible advantage of degarelix on
GnRH agonists in the neoadjuvant use related to radiotherapy
primary treatment. No data from randomized trials significantly
supports this hypothesis. Our meta-analysis showed that the
reduction of prostate volume (that may represent an advantage
for the following radiotherapic treatment) after 90 days was
similar in the degarelix and in the GnRH agonist group (MD=
3.79, 95% CI: 4.84 to 12.41, P=0.38).
A second well studied biochemical profile is that related to PSA
variations. This analysis was possible in 4 out of the 5 trials. In the
CS21 trial as well as faster testosterone suppression, degarelix
was associated with significantly faster PSA reduction versus
leuprolide. However, our meta-analysis, summarizing data from
all 4 trials, showed that the differences in the reduction in PSA
from baseline between degarelix and GnRH agonists at day 28
were not statistically significant (OR=1.48, 95% CI: 0.78–2.81,
P>0.1).
The safety profile of the two compounds is reported in all 5
trials. Unfortunately, we can obtain comparative data only
during the first year of treatment and we cannot compare a long-
term safety. Our meta-analysis shows a similar good profile for
degarelix and GnRH agonists with a low rate of drop out due to
adverse events. The only significant difference was related to
injection-site reactions rate that was significantly higher with
degarelix (OR=10.62, 95% CI: 2.94–38.31, P<0.0001).
Several analyses in the literature suggest a better cardiovascular
safety profile for degarelix.[14,21] Our meta-analysis shows that
treatment related severe cardiovascular side effects (QT interval
increase, angina pectoris, atrial fibrillation, cardiac failure, and
myocardial ischemia) are specifically reported in 3 trials on a
follow-up no longer than 12 months. The incidence of these
events considered all together, was lower in degarelix (1.6%)
than in GnRH agonists (3.6%) group but a statistical significance
was not reached (OR=0.55, 95% CI: 0.26–1.14, P>0.1).
MD-D-16-01463; Total nos of Pages: 11;
MD-D-16-01463
Sciarra et al. Medicine (2016) Vol:No www.medicine.comSmith et al.[14] analyzing data only from CS21 trial, reported
no significant QTmodifications between the two treatments but a
lower incidence of ischemic heart disease in the degarelix (4%)
than in the leuprolide (10%) group. In an open noncomparative
analysis,[21] authors reported that cardiovascular event rates
were similar (P>0.1) before and after degarelix treatment in the
total population and in men without cardiovascular diseases at
baseline. In contrast, event rates were higher after degarelix
treatment in men with cardiovascular diseases at baseline (P=
0.0013).4.1. Limitations from the analysis of oncological results
In particular two review articles[3,15] sustain the significance of
oncological results from degarelix when compared to GnRH
agonists. Klotz et al[15] analyzing data from the 5 randomized
clinical trials, reported a higher rate of PSA progression-free
survival with degarelix than with GnRH agonists, either in the
whole population (HR 0.71, P=0.017) or in patients with
baseline PSAmore than 20ng/mL (HR: 0.74; 95%CI: 0.55–1.00;
P=0=0.052). Klotz et al.[15] described also a better overall
survival with degarelix (HR=0.47; P=0.023) than with GnRH
agonists.
Van Poppel et al.[3] similarly supported the oncological
advantage of degarelix versus GnRH agonists, in particular for
cases with baseline PSA levels more than 20ng/mL. They included
in their analysis the CS21A open-extension, so to have a longer
follow-up at a median of 27.5 months.
Our analysis evidences relevant limitations in particular for the
comparative evaluation of the efficacy and the oncological results
related to degarelix. The oncological evaluation is based only on
one trial (CS21) and it was not the primary endpoint. Data from
trial CS35 are not extensively published and oncological results
are not clearly available from clinical trial.gov.[17] It is not
possible to include in a comparative randomized evaluation the
CS21A extension.[18,19] In this trial the randomized period
remains related to the first year of treatment (CS21 trial)[12] and
after there is a not useful crossover and all cases are treated with
degarelix.
The survival analysis performed by trial CS21 tended to
support an advantage of degarelix on GnRH agonist either in
terms of PSA progression free survival or overall survival.
However, many and relevant uncertainties exist. The population
included is mixed, considering either nonmetastatic or metastatic
cases and this aspect can reduce the statistical power of the study.
The most limiting aspect is the follow-up of the trial (only 365
days). It is not possible to extend this follow-up using the CS21A
trial: after the first year no comparative randomized data are
available. During this follow-up, the numbers of events and in
particular the numbers of deaths are limited, so that overall
survival cannot be significantly evaluated.
Therefore, no meta-analysis can be performed regarding
oncological results and, regarding overall survival, the limited
follow-up (only 12 months) and the limited number of events do
not consent to evaluate advantages from one treatment to the
other.
Always related to the limited follow-up, a PSA progression was
mainly described only in metastatic and baseline PSA more than
20ng/mL cases. In these cases, the probability of arriving at the
final follow-up without PSA progression was higher in patients
receiving degarelix (91.1%; 95% CI: 85.9–94.5) compared to
GnRH agonist (85.9%; 95% CI: 93.8–98.9; P=0.05; log-rank).9Adjusting for baseline disease stage and PSA, these data resulted
in HR of 0.664 (95% CI: 0.385–1.146).
In the main CS35 trial, participants were randomized 2:1 to
treatment with degarelix or goserelin, respectively. All partic-
ipants who completed the CS35 trial after initiation of the CS35A
were eligible to enroll into this extension, provided that their
treatment could continue uninterrupted. Patients entering the
CS35A trial continuedwith the same 3-monthly treatment as they
received in CS35 (i.e., degarelix 480mg or goserelin 10.8mg). It
was intended that patients in CS35A would receive treatment
with degarelix or goserelin for a period of 40 months (including
13 months’ treatment in CS35). It was, however, decided to
prematurely terminate the CS35A trial due to an insufficient
number of patients being enrolled. When the trial was closed 156
cases in degarelix and 80 cases in goserelin group were present.
Maximum exposure of treatment was 111 weeks (in both
treatment arms).[20]
The primary end-point of CS35A was PSA progression free
survival differences at 3 years of treatment. Degarelix was to be
considered noninferior to goserelin if the upper limit of the two-
sided 95% CI of the adjusted hazard ratio was less than or equal
to the noninferiority margin of 1.33. The results of the trial
showed an HR=0.774 (95% CI=0.542–1.106; P=0.1589) that
was consistent with a noninferiority of degarelix on goserelin.
Stratification of data on the basis of tumor stage or baseline PSA
is not available.[20]
The trial reported also the HR for mortality rate at 3 years
between degarelix and goserelin, but the hypothesis of non-
inferiority was considered null (HR=0.595; 95% CI=
0.259–1.368; P=0.2212).[20]5. Conclusions
Our meta-analysis showed the following results: (i) both
treatments were able to maintain testosterone to castration
levels to day 364. In the first 28 days, degarelix produced
castration levels in a higher percentage of cases. No significant
differences were found regarding PSA level variation. (ii) In both
groups, adverse events were mild or moderate and drop-out rate
was comparable and low. The main side effect related to
degarelix was site injection reactions. Severe cardiovascular side
effects were lower, but not significantly, in the degarelix group.
(iii) LUTS showed a significantly higher reduction in the degarelix
group whereas prostate volume reduction was similar compared
to GnRH agonist. (iv) The evaluation of the oncological efficacy
of degarelix in randomized trials is strongly limited by the 12-
month follow-up. Results were mainly presented in terms of PSA
progression, with a significantly higher PSA progression-free
survival in the degarelix group compared to GnRH agonist. PSA
progression occurred more frequently in metastatic and PSA
more than 20ng/mL cases in both treatments. In particular for
high-risk or metastatic cases, the advantage or the noninferiority
of a treatment (degarelix on GnRH agonists) should be
demonstrated in terms of overall survival or clinical progres-
sion-free survival as primary endpoints.References
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